Regulation 16 Amendment of regulation 2
Regulation 2(1)f1 (interpretation), at the appropriate places in the alphabetical order insert—
““EAMS medicinal product” means a medicinal product that—
- (a)
has been included in the Early Access to Medicines Scheme by means of the licensing authority issuing an EAMS scientific opinion in respect of it; and
- (b)
remains in the scheme by virtue of the EAMS scientific opinion not ceasing to have effect in respect of it by virtue of regulation 167D of the 2012 Regulations;”;
““EAMS scientific opinion” is to be construed in accordance with regulation 167C(2)(b) of the 2012 Regulations;”; and
““Early Access to Medicines Scheme” means the scheme of that name established and operated under regulation 167C(1) of the 2012 Regulations;”.